Dr. Erin H Breese, MD, PhD
Claim this profileCincinnati Children's Hospital Medical Center
Expert in Non-Hodgkin's Lymphoma
Expert in Lymphoma
20 reported clinical trials
48 drugs studied
Area of expertise
1Non-Hodgkin's Lymphoma
Global LeaderStage I
Stage II
MTOR positive
2Lymphoma
Global LeaderStage I
Stage II
MTOR positive
Affiliated Hospitals
Clinical Trials Erin H Breese, MD, PhD is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
More about Erin H Breese, MD, PhD
Clinical Trial Related7 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Erin H Breese, MD, PhD has experience with
- Cyclophosphamide
- Prednisolone
- Methotrexate
- Pegaspargase
- Mercaptopurine
- Dexamethasone
Breakdown of trials Erin H Breese, MD, PhD has run
Non-Hodgkin's Lymphoma
Lymphoma
Relapse
Childhood Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Erin H Breese, MD, PhD specialize in?
Erin H Breese, MD, PhD focuses on Non-Hodgkin's Lymphoma and Lymphoma. In particular, much of their work with Non-Hodgkin's Lymphoma has involved Stage I patients, or patients who are Stage II.
Is Erin H Breese, MD, PhD currently recruiting for clinical trials?
Yes, Erin H Breese, MD, PhD is currently recruiting for 4 clinical trials in Cincinnati Ohio. If you're interested in participating, you should apply.
Are there any treatments that Erin H Breese, MD, PhD has studied deeply?
Yes, Erin H Breese, MD, PhD has studied treatments such as Cyclophosphamide, Prednisolone, Methotrexate.
What is the best way to schedule an appointment with Erin H Breese, MD, PhD?
Apply for one of the trials that Erin H Breese, MD, PhD is conducting.
What is the office address of Erin H Breese, MD, PhD?
The office of Erin H Breese, MD, PhD is located at: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229 United States. This is the address for their practice at the Cincinnati Children's Hospital Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.